Posted On: 11/01/2012 4:39:09 PM
Post# of 72447
Latest Headlines for Cellceutix Instant DD
First Patients Recruited and Enrolled in Cellceutix Clinical Trial of Novel Anti-Cancer Drug Kevetrin - Oct 29th, 2012 5:00 am
CELLCEUTIX CORP Financials - Oct 23rd, 2012 11:04 am
Clinical Trials for Cellceutix Novel Anti-Cancer Drug Now Active at Leading Hospitals - Oct 22nd, 2012 5:00 am
Valiant Is On An Acquisition Spree - Will Prurisol Get Under Big Pharma's Skin? - Oct 18th, 2012 11:03 am
CELLCEUTIX CORP Files SEC form 10-K, Annual Report - Oct 12th, 2012 7:30 am
Interview With Leo Ehrlich, CEO Of Cellceutix - Oct 9th, 2012 6:43 am
Clinical Trials Going Active for Cellceutix Anti-Cancer Drug Kevetrin - Oct 8th, 2012 5:00 am
3 Best Biotech Stocks For This Week (Part III) - Sep 24th, 2012 6:41 am
Cellceutix to Commence Clinical Trials for Its Novel Anti-Cancer Drug Kevetrin - Sep 24th, 2012 5:00 am
Cellceutix Plans for European Funded Leukemia Phase 1 Trial - Sep 10th, 2012 5:00 am
5 Pharmaceutical Companies To Present At The Rodman And Renshaw Conference On September 11 - Sep 10th, 2012 4:52 am
Cellceutix Anti-Psoriasis Drug Advances Toward Phase 2 Clinical Trials With Selection of Dr. Reddy's Laboratories for Manufacturing - Sep 4th, 2012 5:00 am
4 Pharmaceutical Companies Moving On News - Aug 6th, 2012 9:05 am
Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber for Start of Clinical Trials - Aug 6th, 2012 5:00 am
Cellceutix Cancer Trial Enrollment Planned for August 2012 - Jul 23rd, 2012 5:00 am
Cellceutix Corporation (OTCBB:CTIX) Meets Manufactures to Synthesize Psoriasis Drug Candidate for Clinical Trials - Video Summary Posted on www.InvestmentPitch.com - Jul 17th, 2012 8:27 pm
Cellceutix Meets Manufacturers to Synthesize Psoriasis Drug Candidate for Clinical Trials; Site Initiation Visit for Clinical Trials of Kevetrin to Happen This Week - Jul 16th, 2012 5:00 am
Cellceutix Sets for Cancer Patient Enrollment in Clinical Trial of Pioneering p53 Cancer Drug - Jul 9th, 2012 5:00 am
CELLCEUTIX CORP Files SEC form 8-K, Unregistered Sale of Equity Securities - Jun 29th, 2012 1:26 pm
Cellceutix Novel Anti-Cancer Drug Kevetrin(TM) Receives IRB and SRC Approvals for Clinical Trials at Harvard's Dana-Farber Cancer Institute - Jun 26th, 2012 5:00 am
(0)
(0)
